ArticleJAMA oncology2018

Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies.

Steven SorscherPubMed ↗Publisher ↗

No numbers read from the abstract.